This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
It further reported that these results underscore the strong and positive effect of the Cleerly products on clinical utility for patients with suspected coronaryarterydisease. “We With Plaque Features Associated with False Positives. Barcelona, Spain. 4 Chiou A, Hermel M, Miller G et al. 7 Bär S, Nabeta T, Maaniitty T.
IntroductionNon-contrast CT calcium scoring (CTCS) exams have been widely used to assess coronaryarterydisease. However, their clinical applications in predicting coronaryarterial remodeling remain unknown. MethodsWe analyzed data from 1,324 patients who underwent both CTCS and CT angiography. 95% CI: 2.54.0;
The designation recognizes the novelty of the technology and the potential to provide a more effective treatment option for patients with coronaryarterydisease. The DynamX bioadaptor has a novel design and mechanism of action designed to return the diseased vessel to a more normal condition, through three distinct phases.
The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, in collaboration with researchers across multiple institutions, has published a new study that challenges the long-held belief that high cholesterol correlates and even directly causes coronaryarterydisease, or plaque buildup in the arteries in metabolically healthy (..)
This designation recognizes the transformative potential of our technology in addressing a critical unmet need in the treatment of patients with coronary chronic total occlusions. We are committed to advancing the field of interventional cardiology and improving patient outcomes through innovation."
At present, machine learning, deep learning, and other AI technologies have been tried to be applied to intelligent diagnostic and decision making, image interpretation, accurate classification, and prognostication of cardiovascular diseases, which has led to broad application prospects and innovation potential.
6 Also in 2023, HeartFlow released its RoadMap Analysis which helps identify and quantify narrowings in the coronaryarteries and has demonstrated a 25% faster CCTA read time. We've experienced a year of notable accomplishments and growth including the expansion of our product portfolio with Plaque Analysis and RoadMap Analysis.
Nevertheless, the relationship between CAC and the susceptibility of a plaque to provoke a thrombotic event remains incompletely understood. These innovations may speed achieving the ultimate goal of providing noninvasively specific and clinically actionable information.
mg reduces the risk of major adverse cardiovascular events (MACE) and supports its use in the treatment of cardiovascular disease. mg)has potential to directly reduce inflammation, which plays a substantial role in the formation and progression of atherosclerotic plaque leading to heart disease, said Matthew J. Budoff, M.D.,
Cleerly is dedicated to creating a new standard of care for heart disease by using FDA-cleared solutions powered by artificial intelligence. With this investment, we look forward to helping Cleerly expand its reach and impact, bringing this potentially life-saving innovation to more patients and health systems nationally.
1 Atherosclerosis is a systemic disease that affects multiple vascular regions and is particularly severe in PAD patients, where up to 80 percent suffer from concurrent coronaryarterydisease (CAD), historically linked with a mortality rate exceeding 50 percent within five years. 101272, [link].
mg reduces the risk of major adverse cardiovascular events (MACE) and supports its use in the treatment of cardiovascular disease. mg)has potential to directly reduce inflammation, which plays a substantial role in the formation and progression of atherosclerotic plaque leading to heart disease, said Matthew J. Budoff, M.D.,
Lowering both contrast and radiation levels enables more frequent scanning for patients with moderate or stage two and three coronaryarterydisease. Advanced scanners provide detailed insights into plaque progression and stabilization. By doing so, we can monitor plaque progression or stabilization.
From breakthrough medications to innovative technologies, there is a lot for cardiometabolic clinicians professionals to celebrate. Personalized Cardiometabolic Care TRANSFORM Program for CoronaryArteryDisease (CAD) : The TRANSFORM program focuses on atherosclerosis-based care strategies rather than traditional risk-based approaches.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
103 
Let's personalize your content